Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19

J Clin Microbiol. 2020 Jul 23;58(8):e00760-20. doi: 10.1128/JCM.00760-20. Print 2020 Jul 23.
No abstract available

Keywords: COVID-19; SARS-CoV-2; coronavirus; emergency use authorization; in vitro diagnostic; nucleic acid amplification; virology.

Publication types

  • Comparative Study
  • Evaluation Study
  • Letter

MeSH terms

  • Betacoronavirus / isolation & purification*
  • COVID-19
  • COVID-19 Testing
  • Centers for Disease Control and Prevention, U.S.
  • Clinical Laboratory Techniques / methods*
  • Coronavirus Infections / diagnosis*
  • Diagnostic Test Approval
  • Humans
  • Molecular Diagnostic Techniques / methods*
  • Nasal Mucosa / virology*
  • Nasopharynx / virology*
  • Nucleic Acid Amplification Techniques / methods
  • Pandemics
  • Pneumonia, Viral / diagnosis*
  • SARS-CoV-2
  • Sensitivity and Specificity
  • United States
  • United States Food and Drug Administration